Article info
PDFHow to do it
Treatment of CIDP
- Correspondence to Dr Simon Rinaldi, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 2JD, UK; simon.rinaldi{at}ndcn.ox.ac.uk
Citation
Treatment of CIDP
Publication history
- Accepted July 10, 2022
- First published September 15, 2022.
Online issue publication
October 18, 2023
Article Versions
- Previous version (28 April 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects
- Increased IP-10 production by blood–nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy
- Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy
- Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy
- Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy
- Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies
- Multifocal motor neuropathy: controversies and priorities
- Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review
- Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial